From Berkeley Lovelace Jr.:
From Zacks: As we head toward the end of 2017, the pharma sector continues to perform well, representing a contrast to 2016 when the sector was under immense pressure due to the drug pricing issue.
From Invesco: The pharmaceutical industry has lagged in recent years, due in part to political uncertainty, which has kept a lid on company share prices.
From Bill Hall: In my most recent Money and Markets articles, I’ve put you on the inside track about a rapidly growing, yet mostly still under-the-radar, industry. One that the world’s super-rich are quietly funding with their own money, in pursuit of potentially eye-popping investment returns.
From Zacks: 2016 turned out to be a challenging year for pharma stocks with the sector facing a lot of criticism for rising drug prices. Although the election results provided a breather for the sector on hopes that drug pricing would not be a key focus area under a Donald Trump presidency, the relief rally […]
With all of the talk from Capitol Hill in regards to prescription pill prices and proposed healthcare reform, today we hone in on the Pharmaceutical segment within the greater Healthcare industry sector in ETF land.
From Brad Hoppmann: The news out of Washington keeps flooding out, and specifically news that’s being made straight from the Oval Office.
From Dana Lyons: The post-2009 bull market in drug stocks is currently being threatened, with a key index reaching a critical technical level.
NASDAQ:MDCO, NYSE:PFE, NYSE:MRK
NASDAQ:CELG, NASDAQ:ALXN, NASDAQ:BIIB, NASDAQ:AMGN
NYSE:PFE, NYSE:MRK, NYSE:LLY
NASDAQ:BIIB, NYSEARCA:XPH, NYSEARCA:IHE, NYSEARCA:PJP, NYSEARCA:XLV